Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics
Fig 3
Survival of Multiple Myeloma patients in Austria from start of 3rd line.
Therapy. illustrates the survival of Myeloma patients in Austria from start of 3rd line therapy in 105 patients documented in AMR median survival was found to be 27 months (0–170 months/ongoing).